You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-PD1/PDL1

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +13 more
  • Bintrafusp Alfa
  • Houston, Texas
    M D Anderson Cancer Center
Oct 13, 2021

Advanced Tumors, Lymphoma, Metastatic Tumors Trial in Changchun, Jinan (HLX301)

Recruiting
  • Advanced Tumors
  • +2 more
  • Changchun, Jilin, China
  • +1 more
Jul 12, 2022

Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

Not yet recruiting
  • Solid Tumor, Adult
  • +2 more
  • (no location specified)
Dec 14, 2022

PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact

Not yet recruiting
  • PDL1- Colorectal Carcinoma
    • (no location specified)
    Jan 11, 2023

    Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

    Not yet recruiting
    • Lung Neoplasm
    • +2 more
    • Tumor samples
    • Bordeaux, France
      CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
    Aug 28, 2023

    Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

    Completed
    • Metastatic Colorectal Adenocarcinoma
    • regorafenib plus anti-PD-1 antibodies
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Jul 4, 2023

    Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

    Recruiting
    • Nasopharyngeal Carcinoma
    • Anti-EGFR and PD-1 inhibitor arm
    • Shanghai, Shanghai, China
      Eye & ENT Hospital of Fudan University
    Nov 26, 2023

    Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

    Not yet recruiting
    • Muscle-Invasive Bladder Carcinoma
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Aug 3, 2023

    Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

    Not yet recruiting
    • Stage IIIA Hepatocellular Carcinoma
    • Radiotherapy combined with TKI and Anti-PD-1 Antibody
    • (no location specified)
    Sep 24, 2023

    Lung Cancer Trial in Madrid (Microbiota Transplant plus anti PD1 therapy, anti PD1 therapy)

    Recruiting
    • Lung Cancer
    • Microbiota Transplant plus anti PD1 therapy
    • anti PD1 therapy
    • Madrid, Spain
      Hospital Universitario Ramón y Cajal
    Oct 3, 2022

    Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT

    Recruiting
    • Lung Cancer Stage III
    • Lung Cancer Stage IV
      • Brest, France
        Chu Brest
      Aug 16, 2023

      SOX2 & PDL1 Expression on Urinary Bladder Carcinoma

      Not yet recruiting
      • Urinary Bladder Neoplasm
        • (no location specified)
        Jun 17, 2022

        Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

        Not yet recruiting
        • Acute Lymphoblastic Leukemia in Pediatric
        • flow cytometric immunophynotyping
        • Sohag, Egypt
          Sohag University Hospital
        Jun 19, 2022

        Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • Chuo-ku, Tokyo, Japan
          National Cancer Center Hospital ( Site 3700)
        Jan 31, 2023

        Basal Cell Carcinoma Trial in Zürich (Cemiplimab Injection [Libtayo])

        Recruiting
        • Basal Cell Carcinoma
        • Cemiplimab Injection [Libtayo]
        • Zürich, Switzerland
          University Hospital Zurich, Clinic of Dermatology
        Nov 3, 2022

        Hepatocellular Carcinoma Trial in Beijing (Sintilimab, Lenvatinib, radiotherapy)

        Recruiting
        • Hepatocellular Carcinoma
        • Beijing, Beijing, China
          Beijing Tsinghua Changgung Hospital
        Jan 5, 2023

        Hepatocellular Carcinoma, HCC, Liver Cancer Trial in Hong Kong (Nivolumab, Hepatectomy)

        Completed
        • Hepatocellular Carcinoma
        • +2 more
        • Hong Kong, Hong Kong
          Queen Mary Hospital
        Jul 20, 2022

        Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Laboratory Biomarker Analysis,

        Active, not recruiting
        • Advanced Malignant Neoplasm
        • +2 more
        • Laboratory Biomarker Analysis
        • +5 more
        • Houston, Texas
          M D Anderson Cancer Center
        Dec 13, 2022

        NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

        Not yet recruiting
        • Non-small Cell Lung Cancer (NSCLC)
        • Alirocumab and Cemiplimab
        • (no location specified)
        Jan 31, 2023

        Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1 Trial in Changchun (nCRT ? (CapeOX+Sintilimab)×6 ?

        Not yet recruiting
        • Locally Advanced Rectal Cancer
        • +2 more
        • nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
        • Changchun, Ji Lin, China
          First Hospital of Jilin University
        Aug 11, 2023

        Advanced Breast Cancer, Breast Tumor Malignant Female Trial in Guangzhou (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

        Completed
        • Advanced Breast Cancer
        • Breast Neoplasm Malignant Female
        • AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
        • Guangzhou, Guangdong, China
          Sun Yat-sen Memorial Hospital of Sun Yat-sen University
        Apr 11, 2023

        Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

        Recruiting
        • Oral Squamous Cell Carcinoma
        • +3 more
        • Camrelizumab (anti-PD-1 inhibitor)
        • Apatinib (anti-VEGFR inhibitor)
        • Shanghai, Shanghai, China
          Ninth People's Hospital, Shanghai Jiao Tong University School of
        Oct 8, 2022

        Lenvatinib Combined Anti-PD1 Antibody for Advanced

        Completed
        • Hepatocellular Carcinoma
        • +2 more
        • Guangzhou, Guangdong, China
          Second Affiliated Hospital of Guangzhou Medical University
        Jul 8, 2022

        Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

        Not yet recruiting
        • Esophageal Squamous Cell Carcinoma
        • Neoadjuvant Chemoimmunotherapy
        • neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
        • (no location specified)
        Feb 14, 2023

        NSCLC, Immunotherapy Trial in Ann Arbor (Dexamthasone)

        Terminated
        • Non-Small Cell Lung Cancer
        • Immunotherapy
        • Ann Arbor, Michigan
          VA Ann Arbor Healthcare System, Ann Arbor, MI
        Jan 6, 2023